Evidence map›Paper›PMID 20585105›Full record

ReviewJournal of the National Cancer Institute2010

Testicular cancer survivorship: research strategies and recommendations.

Lois B Travis, Clair Beard, James M Allan, Alv A Dahl, Darren R Feldman, Jan Oldenburg, Gedske Daugaard, Jennifer L Kelly, M Eileen Dolan, Robyn Hannigan and 12 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the National Cancer Institute, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 4 pooled it
22.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 4 syntheses or guidelines pooled it, 288 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Pooled it
  4. Long-term toxicity of cisplatin in germ-cell tumor survivors.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
    Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Observational
  11. Review
  12. Review
  13. Article
  14. Review
  15. Treatment de-escalation for stage II seminoma.Nature reviews. Urology · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 16 institutions in 6 countries.

Lois B TravisDepartment of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. lois_travis@urmc.rochester.edu
Clair Beard
James M Allan
Alv A Dahl
Darren R Feldman
Jan Oldenburg
Gedske Daugaard
Jennifer L Kelly
M Eileen Dolan
Robyn Hannigan
Louis S Constine
Kevin C Oeffinger
Paul Okunieff
Greg Armstrong
David Wiljer
Robert C Miller
Jourik A Gietema
Flora E van Leeuwen
Jacqueline P Williams
Craig R Nichols
Lawrence H Einhorn
Sophie D Fossa
Memorial Sloan Kettering Cancer Center · USNorwegian Cancer Society · NOProvidence Portland Medical Center · USThe Netherlands Cancer Institute · NLUniversity of Chicago · USUniversity of Massachusetts Boston · USBrigham and Women's Hospital · USHarvard University · USIndiana University – Purdue University Indianapolis · USNewcastle University · GBOslo University Hospital · NORigshospitalet · DKSt. Jude Children's Research Hospital · USUniversity Health Network · CAUniversity Medical Center Groningen · NLUniversity of Oslo · NO

Funding

UMB/DFHCC Comprehensive Cancer Partnership ProgramU56CA118635 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI JENSEN, RODERICK V · 2005 to 2009
$2.5M
NCI NIH HHS 5U56CA118635NCI NIH HHS U56 CA118635
6 · The paper itself

Abstract

Testicular cancer represents the most curable solid tumor, with a 10-year survival rate of more than 95%. Given the young average age at diagnosis, it is estimated that effective treatment approaches, in particular, platinum-based chemotherapy, have resulted in an average gain of several decades of life. This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, decreased fertility, and psychosocial problems. Data on underlying genetic or molecular factors that might identify those patients at highest risk for late sequelae are sparse. Genome-wide association studies and other translational molecular approaches now provide opportunities to identify testicular cancer survivors at greatest risk for therapy-related complications to develop evidence-based long-term follow-up guidelines and interventional strategies. We review research priorities identified during an international workshop devoted to testicular cancer survivors. Recommendations include 1) institution of lifelong follow-up of testicular cancer survivors within a large cohort setting to ascertain risks of emerging toxicities and the evolution of known late sequelae, 2) development of comprehensive risk prediction models that include treatment factors and genetic modifiers of late sequelae, 3) elucidation of the effect(s) of decades-long exposure to low serum levels of platinum, 4) assessment of the overall burden of medical and psychosocial morbidity, and 5) the eventual formulation of evidence-based long-term follow-up guidelines and interventions. Just as testicular cancer once served as the paradigm of a curable malignancy, comprehensive follow-up studies of testicular cancer survivors can pioneer new methodologies in survivorship research for all adult-onset cancer.

Indexed as

AdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCardiovascular DiseasesClinical Trials as TopicCognitionEmploymentEvidence-Based MedicineFatigueGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansInfertility, MaleMaleModels, StatisticalNeoplasm Recurrence, LocalAntineoplastic AgentsPlatinum Compounds

Identifiers

PMID20585105
PMCPMC2914759
OpenAlexW2161993385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.